It draws on a range of analytic perspectives including neurophysiological, communicative, psychosocial, and socio-interactional perspectives in order to examine how these acquired neurological ...

Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its ...

By Bhanvi Satija and Puyaan Singh (Reuters) -Johnson & Johnson said on Monday it will buy neurological drugmaker Intra-Cellular Therapies for $14.6 billion, its biggest deal in at least two years, ...

“The company’s current pipeline is evidence of its capability to generate multiple exciting new investigational drugs for patients with severely debilitating neurological disorders.

We are a mental health practice focused on the evaluation and treatment of neurodevelopmental and acquired neurological conditions. We are currently accepting evaluation and therapy clients for ...

An example of chemical shift imaging of the mouse brain acquired via BioSpec Maxwell ... and neurotransmitter concentrations in neurological disorders. Built upon metabolic signatures, CEST ...

Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in the market for neurological disorder treatments. J&J will buy all of ...